What Does Dexcom (DXCM) Actually Do? Inside the Glucose Sensor Maker Behind G7, Stelo and Insulin Pump Integrations

Dexcom, Inc. (NASDAQ: DXCM) is a medical-device company founded in 1999 and headquartered in San Diego, California. It does not make drugs. It makes continuous glucose monitors, or CGMs: small wearable sensors that read a person's glucose level every few minutes and send the number to a phone, so people with diabetes no longer have to rely only on fingerstick tests. Dexcom is a member of the Nasdaq-100, and its latest quarterly report (Q2 2026, released July 30, 2026) showed $1.308 billion in revenue, up 13% from a year earlier. This post walks through what the company actually sells, who it works with, and who ends up wearing its products.

1. What does Dexcom actually sell?

The core product is a sensor. A thin filament sits just under the skin and measures glucose in the fluid around the body's cells. The sensor is disposable, so a user has to replace it on a fixed schedule, and that replacement cycle is what makes the business recurring. According to Dexcom's annual report, the company earns revenue from disposable sensors, transmitters and optional receiver devices, while a phone app can replace the receiver entirely.

The current lineup has three parts. The Dexcom G7, cleared in the U.S. in December 2022, is the mainstream system for people who manage diabetes with insulin. The G7 15 Day, cleared by the FDA on April 10, 2025, stretches sensor wear to 15.5 days instead of 10 and reported an 8% MARD, a standard accuracy measure where lower is better. Stelo, cleared in March 2024 as the first over-the-counter CGM, is aimed at people who do not use insulin and can be bought without a prescription. Dexcom says it began launching a fully reimagined Stelo app in 2026.

The financial snapshot from the Q2 2026 report: U.S. revenue grew 11%, international revenue grew 19% on a reported basis, and GAAP gross margin was 63.4%. Management raised its full-year 2026 revenue guidance to a range of $5.18 billion to $5.25 billion, which is roughly 11% to 13% growth. For context, Wikipedia lists 2025 revenue at about $4.66 billion.

2. Who does Dexcom work with?

Insulin pump makers are the most important technology partners. Dexcom signed a non-exclusive agreement with Tandem Diabetes Care in 2015, and Tandem's Control-IQ automated insulin delivery system, which pairs a pump with a Dexcom sensor, was cleared by the FDA in December 2019. In February 2020 Dexcom signed a non-exclusive global agreement with Insulet for its Omnipod automated insulin delivery. In practice that means the sensor reads glucose, and the pump adjusts insulin based on the reading. Dexcom's annual report says it integrates with multiple pump manufacturers.

Dexcom also reaches beyond medicine. In November 2024 it announced a $75 million investment in Oura, the smart-ring maker, along with a data partnership; Oura was reported at the time to be valued at more than $5 billion. Earlier, in 2015, it partnered with Verily, the life-sciences arm that grew out of Google, to develop what became the G7.

On the operations side, Dexcom sells through its own sales force and through third-party distributors in North America and abroad. It moved its Medicare business to distributors in fall 2020 and no longer bills Medicare directly for supplies. Sensors are manufactured in Mesa, Arizona, in Malaysia, and the company is building a new facility in Athenry, Ireland. Its main competitor is Abbott's FreeStyle Libre family; Libre 3 was cleared for up to 15 days with a 7.9% MARD, and analysts said the G7 15 Day helps Dexcom compete on wear time. Medtronic's MiniMed is another rival.

3. Who actually uses Dexcom products?

Historically, the answer was people with type 1 diabetes and people with type 2 diabetes who take insulin, because they have the most to gain from real-time glucose alerts. The G7 and G7 15 Day serve that group.

Stelo is the push into a much bigger group. CNBC reported when it was cleared that roughly 25 million people in the U.S. have type 2 diabetes without using insulin. A simpler app with fewer alerts is designed for them and for people who just want to understand how food, sleep and exercise move their glucose. Dexcom also reported positive results from its CONNECT randomized controlled trial of CGM use in people with type 2 diabetes in the same Q2 2026 release, which supports the argument for wider use, though the company will still need broader insurance coverage to make that segment large.

Putting it together: Dexcom sells a disposable sensor and the software around it, works with pump makers and consumer-tech partners to make that data useful, and its users range from people who depend on glucose data for insulin dosing to people simply curious about their metabolism.

This post was written from public company filings and press coverage to explain what Dexcom is and how it earns money. It is not a recommendation to buy or sell any security, so please read it as background information only.

댓글

이 블로그의 인기 게시물

Exploring Intuitive Surgical ISRG: The Technology, Supply Chain, and Market Reach of a Robotic Surgery Pioneer

A Friendly Guide to PACCAR (PCAR): Heavy-Duty Trucks and Global Logistics

O'Reilly Automotive (ORLY): Growth Engine Behind the Automotive Aftermarket